Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: A pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 4, 2006, Pages 427-439

  Glueck, Charles J ^a,c   Haque, Mofiz ^a   Winarska, Magdalena ^a   Dharashivkar, Swapna ^a   Fontaine, Robert N ^b   Zhu, Binghua ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

^b MDL Laboratory   (United States)

^c Cholesterol Center   (United States)

Author keywords

Buerger's disease (BD); Endothelial nitric oxide synthase (eNOS); Methylene tetrahydrofolate reductase (MTHFR) C677T A1298C mutations; Nitric oxide (NO); Stromelysin 1 5A 6A mutation; Vasospasm

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ARGININE; CANNABIS; CYANOCOBALAMIN; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FOLIC ACID; HOMOCYSTEINE; NITRIC OXIDE SYNTHASE INHIBITOR; PYRIDOXINE; STROMELYSIN;

ADULT; AGED; ALLOPATHY; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BUERGER DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; GANGRENE; GENE MUTATION; HUMAN; INTRACTABLE PAIN; LIMB AMPUTATION; MALE; PATHOPHYSIOLOGY; PHLEBITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VASOSPASM;

DNA; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MATRIX METALLOPROTEINASE 3; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MODELS, GENETIC; NITRIC OXIDE SYNTHASE TYPE III; PATIENT SELECTION; PEDIGREE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REFERENCE VALUES; SMOKING; THROMBOANGIITIS OBLITERANS;

EID: 33748501886     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606293429     Document Type: Article

References (45)

1. Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000;343:864.
2. Mills JL, Sr. Buerger's disease in the 21st century: Diagnosis, clinical features, and therapy. Semin Vasc Surg 2003;16:179.
3. Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg 2004;39:176.
4. Di Micco P, Niglio A, Scudiero O, et al. A case of Buerger's disease associated with MTHFR C677T mutation homozygosity: A possible therapeutic support. Nutr Metab Cardiovasc Dis 2004;14:225.
5. Bozkurt AK, Besirli K, Koksal C, et al. Surgical treatment of Buerger's disease. Vascular 2004;12:192.
6. Karila L, Danel T, Coscas S, et al. [Progressive cannabis-induced arteritis: A clinical thromboangiitis obliterans subgroup?]. Presse Med 2004;33:21.
7. Buerger L. Thromboangiitis obliterans: Study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci 1908;136:56 + 7.
8. Murase Y, Yamada Y, Hirashiki A, et al. Genetic risk and gene-environment interaction in coronary artery spasm in Japanese men and women. Eur Heart J 2004;25:970.
9. Hoppmann P, Koch W, Schomig A, et al. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percutaneous coronary interventions. Eur Heart J 2004;25:335.
10. Liu PY, Chen JH, Li YH, et al. Synergistic effect of stromelysin-1 (matrix metallo-proteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction. Thromb Haemost 2003;90:132.
11. Humphries S, Bauters C, Meirhaeghe A, et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J 2002;23:721.
12. Gnasso A, Motti C, Irace C, et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000;20:1600.
13. Nakayama M, Yoshimura M, Sakamoto T, et al. Synergistic interaction of T-786 - >C polymorphism in the endothelial nitric oxide synthase gene and smoking for an enhanced risk for coronary spasm. Pharmacogenetics 2003;13:683.
14. Nakayama M, Yasue H, Yoshimura M, et al. T(-786) - > C mutation in the 5?-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol 2000;86:628.
15. Khurana VG, Sohni YR, Mangrum WI, et al. Endothelial nitric oxide synthase T-786C single nucleotide polymorphism: A putative genetic marker differentiating small versus large ruptured intracranial aneurysms. Stroke 2003;34:2555.
16. Yoshimura M, Yasue H, Nakayama M, et al. Genetic risk factors for coronary artery spasm: Significance of endothelial nitric oxide synthase gene T-786 - > C and missense Glu298Asp variants. J Investig Med 2000;48:367.
17. Inbal A, Freimark D, Modan B, et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999;93:2186.
18. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C - >T polymorphism and risk of coronary heart disease: A metaanalysis. JAMA 2002;288:2023.
19. Fatini C, Sofi F, Gori AM, et al. Endothelial nitric oxide synthase -786T>C, but not 894G>T and 4a4b, polymorphism influences plasma homocysteine concentrations in persons with normal vitamin status. Clin Chem 2005;51:1159.
20. Su Y, Han W, Giraldo C, et al. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1998;19:819.
21. Andersen MR, Walker LR, Stender S. Reduced endothelial nitric oxide synthase activity and concentration in fetal umbilical veins from maternal cigarette smokers. Am J Obstet Gynecol 2004;191:346.
22. Barua RS, Ambrose JA, Eales-Reynolds LJ, et al. Dysfunctional endothelial nitric oxide biosynthesis in healthy smokers with impaired endothelium- dependent vasodilatation. Circulation 2001;104:1905.
23. Cooke JP. The pivotal role of nitric oxide for vascular health. Can J Cardiol 2004;20 Suppl B:7B.
24. Adams MR, McCredie R, Jessup W, et al. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997;129:261.
25. Boger RH, Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol 2001;41:79.
26. MacKenzie A, Wadsworth RM. Extracellular L-arginine is required for optimal NO synthesis by eNOS and iNOS in the rat mesenteric artery wall. Br J Pharmacol 2003;139:1487.
27. Moat SJ, Lang D, McDowell IF, et al. Folate, homocysteine, endothelial function and cardiovascular disease. J Nutr Biochem 2004;15:64.
28. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999;354:407.
29. Hankey GJ, Eikelboom JW, Ho WK, et al. Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust 2004;181:314.
30. Estevez AG, Jordan J. Nitric oxide and superoxide, a deadly cocktail. Ann N Y Acad Sci 2002;962:207.
31. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 2003;108:3042.
32. Csont T, Ferdinandy P. Cardioprotective effects of glyceryl trinitrate: Beyond vascular nitrate tolerance. Pharmacol Ther 2005;105:57.
33. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111.
34. Piyathilake CJ, Macaluso M, Hine RJ, et al. Local and systemic effects of cigarette smoking on folate and vitamin B-12. Am J Clin Nutr 1994;60:559.
35. Balasa W, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 1999;81:739.
36. Balasa W, Gruppo RA, Glueck CJ, et al. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am 2004;86-A:2642.
37. Glueck CJ, Iyengar S, Goldenberg N, et al. Idiopathic intracranial hypertension: Associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 2003;142:35.
38. Nakayama M, Yasue H, Yoshimura M, et al. T-786 - >C mutation in the 5?-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99:2864.
39. Glueck CJ, Goldenberg N, Wang P, et al. Ramifications of four concurrent thrombophilic mutations and one hypofibrinolytic mutation. Clin Appl Thromb Hemost 2004;10:365.
40. Glueck CJ, Goldenberg N, Golnick K, et al. Idiopathic intracranial hypertension: Associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 2005;145:72.
41. Rady PL, Szucs S, Grady J, et al. Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002;107:162.
42. Lekakis J, Papamichael C, Vemmos C, et al. Effects of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects. Am J Cardiol 1998;81:1225.
43. Rossi GP, Taddei S, Virdis A, et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003;41:938.
44. Tsukada T, Yokoyama K, Arai T, et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998;245:190.
45. Shaamash AH, Elsonosy ED, Zakhari MM, et al. Placental nitric oxide synthase (NOS) activity and nitric oxide (NO) production in normal pregnancy, pre-eclampsia and eclampsia. Int J Gynaecol Obstet 2001;72:127.